Fouzia Laghrissi-Thode Net Worth

Fouzia Laghrissi-Thode biography

Dr. Fouzia Laghrissi-Thode M.D. serves as Independent Director of the Company. Dr. Laghrissi-Thode has served on our Board since May 2015. Dr. Laghrissi-Thode has held positions of leadership at AstraZeneca, Roche, Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease and genito-urinary health. She is currently Chief Executive Officer and a member of the board of directors of DalCor Pharmaceuticals. Prior to joining DalCor, Dr. Laghrissi-Thode served as U.S. Vice President for the renal-cardio therapy area at AstraZeneca, Head of the South San Francisco site, and the chief executive officer of ZS Pharma, Inc. She was formerly vice president of the cardiovascular and metabolism therapy area at AstraZeneca. Dr. Laghrissi-Thode holds an M.D. from the University of Tours School of Medicine in France, is board certified in psychiatry and was an adjunct professor of psychiatry at the University of Pittsburgh. Our Board believes that Dr. Laghrissi-Thode’s extensive experience in the pharmaceutical industry and field of psychiatry qualifies her to serve on our Board.

What is the salary of Fouzia Thode?

As the Independent Director of Minerva Neurosciences Inc, the total compensation of Fouzia Thode at Minerva Neurosciences Inc is $107,197. There are 14 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of $2,842,430.

How old is Fouzia Thode?

Fouzia Thode is 57, he's been the Independent Director of Minerva Neurosciences Inc since 2015. There are 14 older and 5 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.

What's Fouzia Thode's mailing address?

Fouzia's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC.,, 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.

Insiders trading at Minerva Neurosciences Inc

Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... e Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.

What does Minerva Neurosciences Inc do?

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its

Minerva Neurosciences Inc executives and stock owners

Minerva Neurosciences Inc executives and other stock owners filed with the SEC include:

• Michael Davidson,
  Chief Medical Officer
• Devin Smith,
  Senior Vice President, General Counsel
• Remy Luthringer,
  Chief Executive Officer and Executive Chairman of the Board of Directors
• Geoffrey Race,
  Executive Vice President, Chief Financial Officer and Chief Business Officer
• Dr. Remy Luthringer Ph.D.,
  Exec. Chairman & CEO
• Frederick Ahlholm,
  Senior Vice President, Chief Accounting Officer
• Dr. Rémy Luthringer,
  Exec. Chairman & CEO
• Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA,
  Pres
• Dr. Jay B. Saoud Ph.D.,
  Consultant
• William Doyle,
  Lead Independent Director
• Jan van Heek,
  Independent Director
• Jeryl Hilleman,
  Independent Director
• Hans Hasler,
  Independent Director
• David Kupfer,
  Independent Director
• Fouzia Laghrissi-Thode,
  Independent Director
• William Boni,
  IR Contact Officer
• Jay Saoud,
  Senior Vice President, Head of Research and Development
• Joseph Reilly,
  Chief Operating Officer, Senior Vice President
• Dr. Ramana Kuchibhatla Ph.D.,
  Sr. VP and Head of R&D
• Dr. Michael Davidson M.D.,
  Chief Medical Officer
• Joseph Reilly,
  Sr. VP & COO
• Frederick W. Ahlholm CPA, CPA,
  Chief Financial Officer
• William B. Boni,
  VP of Investor Relations & Corp. Communications
• Marc D Beer,
  Director
• Mark S. Levine,
  SVP,General Counsel & Sec.
• Michele Ollier,
  Director
• Venture Associates Iii Ltd ...,
  
• Nico Vandervelpen,
  Director
• Rubertis Francesco De,
  Director
• Richard E. Russell,
  President
• & Johnson Johnson & Johnson...,
  
• Capital Iii Llc Care Capita...,
  
• Coelho Rogerio Vivaldi,
  President and CEO
• Lorenzo Pellegrini,
  Director
• Geoff Race,
  President
• Plc Barclays,
  10% owner